# Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation

Study · id `cardio:ct-nct07405671` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07405671](<https://clinicaltrials.gov/study/NCT07405671>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07405671

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 988 participants.

## Technical summary

Registry record NCT07405671. Randomized; no masking; primary purpose treatment. Start 2026-09 (anticipated); primary completion 2029-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 988 participants (planned count; ClinicalTrials.gov record NCT07405671, source copy `cardio:ctgov-nct07405671-2026-10-21`, retrieved 2026-10-26)
- Planned start: 2026-09 (anticipated) (ClinicalTrials.gov record NCT07405671, source copy `cardio:ctgov-nct07405671-2026-10-21`, retrieved 2026-10-26)
- Primary completion: 2029-12 (anticipated) (ClinicalTrials.gov record NCT07405671, source copy `cardio:ctgov-nct07405671-2026-10-21`, retrieved 2026-10-26)
- Completion: 2029-12 (anticipated) (ClinicalTrials.gov record NCT07405671, source copy `cardio:ctgov-nct07405671-2026-10-21`, retrieved 2026-10-26)
- Countries: Belgium (ClinicalTrials.gov record NCT07405671, source copy `cardio:ctgov-nct07405671-2026-10-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07405671-2026-10-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation
- Acronym: ReCAST AF
- Condition: Atrial Fibrillation (AF)
- Condition: Coronary Artery Disease
- Intervention (Drug): flecainide
- Intervention (Drug): Sotalol or Amiodarone
- Lead sponsor: Universitaire Ziekenhuizen KU Leuven
- Lead sponsor class: OTHER
- Collaborator: Research Foundation Flanders
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Universitaire Ziekenhuizen KU Leuven (`cardio:org-universitaire-ziekenhuizen-ku-leuven`)

## Provenance

Content hash: 24fd0cf5757c5a3812b36e6992b6c9804ee1605066146dffe93faf64b695b7fd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
